Shares of Genta slid by over a third yesterday after the FDA posted a "ho hum" staff assessment of the biotech firm's leukemia drug, Genasense.
More here.
Looks like the FDA might be "toughening up" their attitude to these so-called cancer "Wonder Drugs".
The only wonder about most of them is that one wonders how they can command such high prices!
Ah! but we really know why, dont we?
No comments:
Post a Comment